Healthcare / BiotechnologyNasdaqCM
$64.40
-0.64 (-0.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-7.9M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$431M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.0%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-13.7M · FCF $-12.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | — | — | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $-13.7M | $-13.7M | $-15.6M | $-8.4M | $-10.5M | $-9.1M | $-6.3M | $-4.2M | $-3.2M | $-16.6M | $-1.2M |
| EBITDA | $-16.7M | $-16.7M | $-16.2M | $-8.8M | $-10.5M | — | — | — | — | — | — |
| EPS | -1.85 | -1.85 | -4.11 | -3.04 | -4.15 | — | — | — | — | — | — |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.00 | 0.00 | — | — | 0.00 | — | — | — | — | — | — |
| Current Ratio | 56.05 | 56.05 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-12.2M | $-12.2M | $-6.4M | $-7.9M | $-7.2M | — | — | — | — | — | — |
| Returns | |||||||||||
| ROE | -10.0% | -10.0% | -28.3% | -150.4% | -104.2% | -48.1% | -40.2% | -33.5% | -46.7% | -172.1% | -41.9% |
| Valuation | |||||||||||
| P/B | 3.46 | 3.46 | 1.58 | 1.05 | 3.24 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| EPS Growth | 55.0% | 55.0% | -35.2% | 26.7% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+103.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.11 → -1.85
Residual
+103.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.